Truist Securities Reiterates Buy Rating on Abbvie (ABBV) Despite Humira Erosion, With Focus on Skyrizi/Rinvoq
Tweet Send to a Friend
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $160.00 price target on Abbvie (NYSE: ABBV) following results, which ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
